- Investopedia•16 minutes ago
Gilead is targeting the high-risk hepatitis C group of individuals born between 1945 and 1965.
- Motley Fool•3 hours ago
Wall Street has assigned some cheap valuations to The Greenbrier Companies, Alliance Resource Partners, and Gilead Sciences.
- Market Realist•4 hours ago
Besides its tenofovir alafenamide–based HIV drugs, Gilead Sciences expects solid uptake for its pre-exposure prophylaxis (or PrEP) HIV therapy, Truvada, in 2017.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||69.22 x 1300|
|Ask||69.23 x 800|
|Day's Range||68.43 - 69.43|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.98|
|Dividend & Yield||2.08 (3.00%)|
|1y Target Est||N/A|